Drugs

Warning Letters 2011

These letters are supplied by the CDER Freedom of Electronic Information Office. This page only covers Office of Prescription Drug Promotion (formerly Division of Drug Marketing, Advertising and Communications) and CDER Headquarters Warning Letters. 

For District Office Warning Letters see the Main FDA FOI Warning Letters Page.  Some of the letters have been redacted or edited to remove confidential information. Matters described in FDA warning letters may have been subject to subsequent interaction between FDA and the recipient of the letter that may have changed the regulatory status of the issues discussed in the letter.  If you wish to obtain available additional information on the current status of an issue in a particular warning letter or notice of violation on this website, please contact the Agency or the recipient of the letter directly.  Inquiries to FDA should be sent to:

Food and Drug Administration
Freedom of Information Staff (HFI-35)
5600 Fishers Lane, Rockville, MD 20857

Instructions for how to submit an FOI request can be found on the FDA FOI Page.

 

Office of Prescription Drug Promotion

 Company/Individual Product/Issue Issue Date

Celgene Corporation

NDA 021660 Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) 12/23/11

Dr. Reddy's Laboratories, Inc.

ANDA 91316 Fondaparinux Sodium Solution for subcutaneous injection 12/22/11

Mutual Pharmaceutical Company, Inc.

NDA 022352 Colcrys (colchicine, USP) tablets for Oral use 12/20/11

Sunovion Pharmaceuticals, Inc.

NDA 200603 Latuda (lurasidone HCl) Tablets 12/14/11

NeurogesX, Inc.

NDA 022395 Qutenza (capsaicin) 8% patch 12/13/11

EUSA Pharma (USA), Inc.

BLA 103608 ProstaScint Kit (Capromab Pendetide) 12/13/11

Lantheus Medical Imaging, Inc.

NDA 17771 Technelite (Technetium Tc 99m Generator) 10/25/11

Otsuka Pharmaceutical Development and Commercialization, Inc.

NDA 020954 Busulfex (busulfan) Injection 10/17/11

Alcon Research, Ltd.

NDA 021545 Pataday (olopatadine hydrochloride ophthalmic solution) 0.2% 10/14/11

Pfizer, Inc.

NDA 021928 Chantix (varenicline) Tablets, NDA 021540 Caduet (amlodipine besylate/atorvastatin calcium) Tablets, NDA 019787 Norvasc (amlodipine besylate) Tablets 8/31/11

Ortho-McNeil-Janssen Pharmaceuticals, Inc.

NDA 022304 Nucynta (tapentadol) immediate-release oral tablets C-II 8/26/2011

 CEL-SCI Corporation

Multikine (Leukocyte Interleukin) Injection 8/5/11

Aton Pharma, a Division of Valeant Pharmaceuticals North America LLC

NDA 010104 Mephyton (phytonadione) Vitamin K1 Tablets 8/2/11

ISTA Pharmaceuticals

NDA 021664 Bromday (bromfenac ophthalmic solution) 0.09% 7/13/11

AOI Pharmaceuticals, Inc./Keryx Biopharmaceuticals, Inc.

KRX-0401 (perifosine) 6/30/11

Cephalon, Inc.

NDA 021248 Trisenox (arsenic trioxide) injection 6/21/11

Nycomed US,  Inc.

NDA 021005 Solaraze (diclofenac sodium) Gel, 3% 6/17/11

Dow Pharmaceutical Sciences, Inc.

NDA 050819 Acanya (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/2.5% 6/16/11
Novartis Pharmaceuticals Corporation NDA 021802 Focalin XR (dexmethylphenidate hydrochloride) Extended-Release Capsules Cll 5/31/11

Noven Pharmaceuticals, Inc.

NDA 021299 Pexeva (paroxetine mesylate) Tablets 5/24/11

Shire Pharmaceuticals, Inc.

NDA 021977 Vyvanse (lisdexamfetamine dimesylate) Capsules, CII 5/6/11

Warner Chilcott (US, LLC

NDA 022560 Atelvia (risedronate sodium) Delayed-release Tablets 5/5/11

ChemGenex Pharmaceuticals

Omapro (omacetaxine mepesuccinate) for Injection 4/28/11

Forest Laboratories, Inc.

NDA 022256 Savella (milnacipran HCl) Tablets 4/28/11

G. Pohl-Boskamp GmbH & Co. KG c/o Arbor Pharmaceuticals, Inc.

NDA 018705 Nitrolingual Pumpspray (nitroglycerin lingual spray) 4/26/11

Inspire Pharmaceuticals, Inc.

NDA 050810 AzaSite (azithromycin ophthalmic solution) 1% 4/14/11

Three Rivers Pharmaceuticals, LLC

BLA 103663 Infergen (interferon alfacon-1) injection for subcutaneous use 3/21/11

Taro Pharmaceuticals USA, Inc.

NDA 18613 Ovide (malathion) lotion, 0.5% 3/11/11

Amag Pharmaceuticals, Inc.

NDA 22180 Feraheme (ferumoxytol) Injection for IV use 2/17/11

Genentech, Inc.

NDA 21455 Boniva (ibandronate sodium) Tablets 1/7/11

DENTSPLY Pharmaceutical

NDA 21451 Oraqix (lidocaine and prilocaine periodontal gel) 2.5%/2.5% 1/4/11

  

Office of Drug Security, Integrity and Recalls

 

 Company/Individual Product/Issue Issue Date
Eugeniu Rusu/Sphere
(WARNING LETTER)
Internet Marketing of Unapproved and Misbranded Drugs 9/21/11

Galyna/Ivan Podornikova
(WARNING LETTER)

Internet Marketing of Unapproved and Misbranded Drugs 9/21/11

 

Office of Unapproved Drugs and Labeling Compliance

 

 Company/Individual Product/Issue Issue Date
Union Springs Pharmaceuticals, LLC
(WARNING LETTER)
Marketing of MyClyns Personal Protection Spray 5/23/11

 

Office of Manufacturing and Product Quality

 Company/Individual Product/Issue Issue Date
Labor L+S AG
(WARNING LETTER)
manufacture of Finished Pharmaceuticals 12/15/11
Merck KGaA
(WARNING LETTER)
manufacture of APIs and reporting changes to an approved application 12/15/11

Novartis International AG
(WARNING LETTER)

manufacture of Finished Pharmaceuticals 11/18/11
Akzo Nobel Chemicals, S.A. de C.V.
(WARNING LETTER)
manufacture of APIs 11/16/11
Xylo Chem Industries
(WARNING LETTER)

 
manufacture of APIs 11/15/11
Jenahexal Pharm GmbH
(WARNING LETTER)
manufacture of Finished Pharmaceuticals 10/19/11
SmithKline Beecham Limited
(WARNING LETTER)
manufacture of Finished Pharmaceuticals 10/7/11
Yag-Mag Labs Private Limited
(WARNING LETTER)
manufacture of APIs 9/12/11
Sichuan Pharmaceutical Co., LTD
(WARNING LETTER)
manufacture of APIs 9/9/11
Nanjing Maohai Biotech Co.
(WARNING LETTER)
manufacture of drugs 8/5/11
Zhejiang Casing Animal By-Products Co. Ltd.
(WARNING LETTER)
manufacture of drugs 8/5/11
Pharmaceutical Company Jelfa SA
(WARNING LETTER)
regulations for Finished Pharmaceuticals 7/14/11

Cadila Healthcare Limited
(WARNING LETTER)

regulations for Finished Pharmaceuticals 6/21/11
Dr. Reddy's Laboratories Limited
(WARNING LETTER)
manufacture of APIs 6/3/11
Aurobindo Pharma Limited
(WARNING LETTER)
regulations for Finished Pharmaceuticals 5/20/11
Alpha Laboratories
(WARNING LETTER)
regulations for Finished Pharmaceuticals 5/5/11
Moehs Iberica, SL
(WARNING LETTER)
manufacture of APIs 4/14/11

Ningbo Smart Pharmaceutical Co. Ltd.
(WARNING LETTER)

manufacture of APIs 3/30/11
Sanofi Aventis Deutschland GmbH
(WARNING LETTER)
 
regulations for Finished Pharmaceuticals 2/9/11
Teva Pharmaceutical Industries, Ltd
(WARNING LETTER)
regulations for Finished Pharmaceuticals 1/31/11

 

 

Office of Compliance/Immediate Office

 Company/Individual Product/Issue Issue Date

Changzhou Jialing Medicine Industry Co Ltd
(WARNING LETTER)

Drug Registration and Listing 12/2/11

 

 

 

Office of Scientific Investigations

 Company/Individual Product/Issue Issue Date
Bay Regional Medical Center IRB
(WARNING LETTER)
Institutional Review Board 12/29/11
Betty Tuller, Ph.D.
(WARNING LETTER)
Clinical Investigator 11/21/11
Leslie E. Diaz, MD
(WARNING LETTER)
Clinical Investigator 11/4/11
Laura A. Teasley, MD
(WARNING LETTER)
Clinical Investigator 10/14/11
Columbia University Medical Center RDRC
(WARNING LETTER)
Radioactive Drug Research Committee (RDRC) 9/20/11

Covenant Healthcare IRB
(WARNING LETTER)

Institutional Review Board (IRB) 9/7/11

John Caton, Jr, MD
(WARNING LETTER)

Clinical Investigator 8/26/11
Yale Cohen, MD
(WARNING LETTER)
Clinical Investigator 8/12/11
Essex IRB, Inc.
(WARNING LETTER)
Institutional Review Board 7/26/11

Cetero Research
(UNTITLED LETTER)

Bioequivalence 7/26/11
Linda D. Bosserman, MD
(WARNING LETTER)
Clinical Investigator 7/19/11

Joseph B. Michelson, MD
(WARNING LETTER)

Clinical Investigator 7/6/11

Jeffrey Horowitz, MD
(WARNING LETTER)

Clinical Investigator 3/21/11

Dr. Martin Zaiac
(WARNING LETTER)

Clinical Investigator 3/21/11
John Griffin, MD
(WARNING LETTER)
Clinical Investigator 3/14/11
Margaret F. Thurmond-Anderle, MD
(WARNING LETTER)
Clinical Investigator 2/25/11

John F. Simmons, MD
(WARNING LETTER)

Clinical Investigator 2/18/11
Vaughn H. Mancha, Jr., MD
(WARNING LETTER)
Clinical Investigator 2/17/11

Judith Ratzan, MD
(WARNING LETTER)

Clinical Investigator 2/16/11

Page Last Updated: 03/14/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English